Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors
ConclusionsResults indicate that chemotherapy-induced spatial memory deficits in mice can be prevented, but not reversed by the use of acetylcholinesterase inhibitors concomitant with chemotherapy, suggesting that these agents should be investigated further for the prevention of chemobrain. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 13, 2019 Category: Cancer & Oncology Source Type: research

A high AR:ER α or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer
AbstractPurposeApproximately 30% oestrogen receptor alpha (ER α)-positive breast cancer (BC) patients exhibit intrinsic or recurrent resistance to adjuvant endocrine therapy with tamoxifen. The androgen receptor (AR) is expressed in about 90% of ERα-positive patients, with particularly high expression in tamoxifen-resistant tumours. Prostate-derived Ets fact or (PDEF), which is a co-regulator of AR, plays a role in tamoxifen resistance in ERα-positive BC. The purpose of this research was to analyse the potential roles of AR, PDEF and ERα levels in the response to tamoxifen resistance in ERα-po...
Source: Cancer Chemotherapy and Pharmacology - July 11, 2019 Category: Cancer & Oncology Source Type: research

Correction to: Population pharmacokinetics of PF ‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin ® ) in patients with HER2‑positive metastatic breast cancer
The article “Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer ” written by Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 3rd May 2019 without open access. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 10, 2019 Category: Cancer & Oncology Source Type: research

Population pharmacokinetics of trabectedin in adolescent patients with cancer
ConclusionsThe adult population pharmacokinetic model adequately described the trabectedin plasma concentrations and its variability in the pediatric population of patients involved in this assessment that mostly comprised adolescents. The trabectedin systemic exposure achieved in this population was comparable (within 12%) to the exposure obtained in adult population when the same dose, expressed in mg/m2, was administered. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 8, 2019 Category: Cancer & Oncology Source Type: research

Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway
ConclusionsTaken together, the results of our study demonstrate that celastrol sensitizes glioma cells to TRAIL via the death receptor pathway and that DR5 plays an important role in the effects of this cotreatment. The results indicate that this cotreatment is a promising tumor-killing therapeutic strategy with high efficacy and low toxicity. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - July 8, 2019 Category: Cancer & Oncology Source Type: research

Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure –QTc in patients with advanced or refractory solid tumors
AbstractPurposeTo characterize the effect of erdafitinib on electrocardiogram (ECG) parameters and the relationship between erdafitinib plasma concentrations and QTc interval changes in patients with advanced or refractory solid tumors.MethodsTriplicate ECGs and continuous 12-lead Holter data were collected in the dose escalation part (Part 1) of the first-in-human study, with doses ranging from 0.5 to 12  mg. Triplicate ECG monitoring continued in Parts 2–4 where 2 dose regimens selected from Part 1 were expanded in prespecified tumor types. Analyses of ECG data included central tendency analyses, identificatio...
Source: Cancer Chemotherapy and Pharmacology - July 6, 2019 Category: Cancer & Oncology Source Type: research

Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer
AbstractBackground/objectivePlatinum-refractory or -resistant ovarian cancer (PRROC) is associated with poor prognosis and low response to further chemotherapy. We investigated predictors of effectiveness of following treatments for PRROC.Patients and methodsWe included 380 patients diagnosed with stage I –IV ovarian, fallopian tube, or primary peritoneal cancer, who were treated at the National Cancer Center Hospital in Japan from January 2007 to December 2014 and recurred after initial treatment, who had a platinum-refractory or -resistant relapses and received chemotherapy, in this single-center , retrospective st...
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin ® ) in patients with HER2-positive metastatic breast cancer
ConclusionsPF-05280014 and trastuzumab-EU had similar PK parameters and influential PK covariates in patients with HER2-positive mBC. These results provided further evidence in patients for PK similarity between PF-05280014 and trastuzumab-EU.Clinical trial registrationClinicalTrials.gov, NCT01989676. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Renin –angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis
This study assessed the risk factors for proteinuria induced by bevacizumab or ramucirumab a nd the relationship between renoprotective effect of RAS inhibitors and blood pressure control.MethodsA retrospective observational analysis was conducted at Tokyo Women ’s Medical University, Medical Center East from June 2015 to May 2018. Multivariate logistic regression analysis was used to identify risk factors for proteinuria induced by treatment with bevacizumab and ramucirumab. Renoprotective effect was assessed by analyzing blood pressure data in associati on with the use of RAS inhibitors.ResultsOut of 208 patients i...
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
ConclusionsBased on the population pharmacokinetic analysis of T-DM1 conjugate and pertuzumab, pharmacokinetics are similar across different lines of treatment and stages of disease including previously untreated MBC patients, and no DDIs were identified for combined use of T-DM1 and pertuzumab. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer
ConclusionsHigh expression of GHET1 was related with the low sensitivity to Gemcitabine of BC; GHET1 contributed to chemotherapeutic resistance to Gemcitabine in BC through up-regulating ABCC1 expression. Our findings are helpful to expound the molecular mechanism of chemotherapeutic resistance in BC. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
ConclusionsThis analysis highlights that tumour size dynamics differ between different treatments and across lines of treatment. The analysis further suggests that these differences could be a manifestation of differing resistance mechanisms. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer
ConclusionsCrizotinib plasma exposure following coadministration with dexamethasone was similar to that when crizotinib was administered without dexamethasone, indicating dexamethasone has no effect on crizotinib exposure or efficacy. Other CYP3A inducers with similar potency would likewise have no clinically relevant effect on crizotinib exposure. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
AbstractBackgroundSunitinib is approved for treatment of adults with imatinib-resistant gastrointestinal stromal tumor (GIST) or imatinib intolerance.MethodsThis single-arm, multicenter, multinational phase I/II clinical trial (NCT01396148) enrolled eligible patients aged 6 to
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Clinical characteristics, treatment patterns and outcomes of patients older than 80  years diagnosed with DLBCL in China over a 10-year period
ConclusionsHigh response rate was concluded on very elderly DLBCL patients ( ≥ 80 years old) with reduced-dose R-CHOP. However, the very elderly patients with NCCN-IPI score ≥ 5 would lead to poor outcome. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Orally administered salecan ameliorates methotrexate-induced intestinal mucositis in mice
ConclusionsSalecan has potential advantages in the treatment of MTX-induced intestinal mucositis, and its protective effect is mainly attributed to its antioxidant and immunomodulatory properties. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65  years with extensive-stage small cell lung cancer: a phase II clinical trial
AbstractPurposeThis phase II, multicenter, single arm clinical study was first performed to evaluate the therapeutic efficacy and safety of the regimen —a combination of lobaplatin (LBP) and etoposide (VP-16)—and investigate the pharmacokinetics of LBP in Chinese men older than 65 years with extensive-stage small cell lung cancer (SCLC).MethodsPatients older than 65 were treated with the combination of LBP and VP-16 for 4 –6 cycles through intravenous drip. The initial dose of VP-16 was 100 mg/m2/day for d1-d3 in each 21-day cycle, while LBP was administrated for d1 in each cycle based on creati...
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
ConclusionsThe cytarabine and daunorubicin in CPX-351 liposomes were metabolized and excreted similarly to conventional formulation; however, plasma pharmacokinetics were altered. CPX-351 did not prolong the QT interval, suggesting that CPX-351 may induce less cardiotoxicity than previously reported for conventional daunorubicin.Trial registrationClinicaltrials.gov identifier: NCT02238925. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting
ConclusionAdding olanzapine to antiemetic therapy with aprepitant, a 5-HT3 receptor antagonist and dexamethasone improved CINV control in patients receiving carboplatin-containing chemotherapy. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand –foot syndrome: a newly recognized toxicity
We describe cutaneous SCC of the plantar foot in two patients exposed to high doses of PLD. A 50-year-old man with angiosarcoma received a total PLD dose of 1350  mg/m2 and developed cutaneous SCC of bilateral plantar feet. A 45-year-old woman with cutaneous T-cell lymphoma was treated with a total PLD dose of 1142  mg/m2 with subsequent diagnosis of cutaneous SCC of the right plantar foot. No risk factors for SCC of the plantar foot were identified in either patient. Cutaneous SCC is likely an unreported side effect of prolonged exposure to PLD. An extended duration of hand –foot syndrome from other anti-c...
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice
ConclusionsResults of the present study showed that the oral administration ofS. cerevisiae UFMG A-905 protected mice against mucositis induced by 5-FU, and that this effect was potentiated when the yeast was enriched with selenium. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [ 14 C]-labeled idasanutlin and an intravenous tracer dose of [ 13 C]-labeled idasanutlin in a single cohort of patients with solid tumors
ConclusionThe clinical implications of this study support the conclusion that renal impairment is unlikely to significantly impact exposure to idasanutlin and M4 metabolite, whereas a significant hepatic impairment may potentially alter exposure to the parent drug and/or metabolite(s). The potential for drug –drug interactions is low. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Stress resilience and survival among cancer patients: is there any absolute truth?
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Qualitative and quantitative variations in liver function thresholds among clinical trials in cancer: a need for harmonization
ConclusionsThere is a marked heterogeneity in the liver function definitions used across cancer clinical trials even when the potential for drug toxicity and altered drug metabolism is significant. Harmonization of criteria will streamline eligibility and mitigate variations in key outcomes across trials. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

Efficacy of immunotherapy, gut microbiota and impact of antibiotic use: are there confounding factors?
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 13, 2019 Category: Cancer & Oncology Source Type: research

A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
ConclusionsThe combination of eribulin and carboplatin demonstrated antitumor activity; however, recent therapeutic advances may be more promising approaches for first-line treatment of NSCLC.Clinical trial registration NCT00268905. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 12, 2019 Category: Cancer & Oncology Source Type: research

Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers
AbstractThe phosphatidylinositol 3-kinase (PI3K) pathway is a promising therapeutic target for various cancers. BGT226 is a pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor. The tolerability and pharmacokinetics/pharmacodynamics of BGT226 were investigated in a phase I study in Japanese patients with advanced solid cancers. BGT226 was orally administered on days 1, 3, and 5 of each week. The initial dose of 10  mg was subsequently escalated to 20, 40, 80, and 100 mg in a cohort of three patients. Pharmacokinetics and pharmacodynamics were investigated using plasma, normal skin, and tumor samples. A tot...
Source: Cancer Chemotherapy and Pharmacology - June 12, 2019 Category: Cancer & Oncology Source Type: research

The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors
ConclusionsThese data show a relevant, treatment-related increase in QTcF after treatment with three doses of lapatinib 2000  mg. This study confirms the need for caution in patients with solid tumors treated with lapatinib, and who are concomitantly receiving drugs that are strong CYP3A inhibitors and/or prolong the QTc. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 11, 2019 Category: Cancer & Oncology Source Type: research

Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
AbstractGastric cancer (GC) is the third cause of cancer-related death worldwide. Patients with unresectable GC can be treated with chemotherapy such as paclitaxel, which is a microtubule stabilizer. The use of nanoparticle albumin-bound paclitaxel (nab-ptx) avoids hypersensitivity reactions due to the absence of solvent needed to dissolve paclitaxel and it can be administered at higher doses. The ABSOLUTE randomized phase-3 clinical trial showed the non-inferiority of the nab-ptx used every week compared to the solvent-based paclitaxel used every week. This review describes the current advancements of the use of nab-ptx i...
Source: Cancer Chemotherapy and Pharmacology - June 11, 2019 Category: Cancer & Oncology Source Type: research

Pharmacokinetic and exposure –response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
ConclusionsPertuzumab exposure in JACOB was consistent with prior studies in advanced gastric cancer and breast cancer. The 840  mg q3w dose allowed the majority of patients in JACOB to achieve target pertuzumab concentrations and appears to be an appropriate dose selection. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 10, 2019 Category: Cancer & Oncology Source Type: research

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody –drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
ConclusionsAMG 595 exhibited favorable pharmacokinetics and is a unique therapy with possible benefit for some patients with EGFRvIII-mutated GBM with limited therapeutic options. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - June 1, 2019 Category: Cancer & Oncology Source Type: research

LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma
ConclusionsLncRNA SNHG16 regulated cellular processes in osteosarcoma by sponging miR-98-5p, and SNHG16 may be a new and effective molecular therapeutic target for osteosarcoma. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients
ConclusionWeekly carboplatin and paclitaxel might be more tolerable and is as effective as 3 weekly carboplatin and weekly paclitaxel schedule in metastatic elderly NSCLC patients. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling
ConclusionsThis study is the first to report that lidocaine acts as an angiogenesis inhibitor. The findings provide preclinical evidence into the potential mechanisms by which lidocaine may negatively affect cancer growth and metastasis. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
ConclusionAMG 172 exhibited a favorable pharmacokinetic profile in patients with relapsed/refractory ccRCC and showed evidence suggestive of limited antitumor activity. Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer
AbstractPurposeDespite positive responses in phase II clinical trials, the bioreductive prodrug apaziquone failed to achieve statistically significant activity in non-muscle invasive bladder cancer in phase III trials. Apaziquone was administered shortly after transurethral resection and here we test the hypothesis that haematuria inactivates apaziquone.MethodsHPLC analysis was used to determine the ability of human whole blood to metabolise apaziquone ex vivo. An in vitro model of haematuria was developed and the response of RT112 and EJ138 cells following a 1-h exposure to apaziquone was determined in the presence of uri...
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents
ConclusionsThe new model is capable of describing different tumor dynamics including tumor eradication and tumor regrowth with different rates, and can be calibrated using data from standard xenograft experiments. TSE and related concepts can be used to predict tumor shrinkage and eradication, and have the potential to guide new experiments and support translations from animals to humans. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model
ConclusionsThe present study demonstrates the power of the PDOX model to identify the novel effective treatment strategy of the combination of OLA, GEM and DOC for drug-resistant soft-tissue sarcoma. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

A phase I study of gemcitabine  + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors
ConclusionsThe MTD/RPTD of GD is gemcitabine 1000  mg/m2 weekly for 3 of 4 weeks and dasatinib 50  mg PO BID. The clinical activity of GD seen in this study was modest, and does not support its further investigation in pancreatic cancer. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer
ConclusionsPlGF gene expression in gastric cancer tissues could be a predictive indicator of AGC treatment by RAM. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Pharmacokinetic and exploratory exposure –response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
ConclusionOverall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study
ConclusionsThe 3-year OS and LFFS of patients who underwent DCF-RT were higher than those in the previous studies. Although the high rate of myelosuppression requires careful management, DCF-RT is a safe and effective modality for CEC. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

d,l -Methadone does not improve radio- and chemotherapy in glioblastoma in vitro
ConclusionsAsd,l-methadone reduces glioblastoma cell viability only when concentrations are used that had been reported to be toxic to patients and as there were no interactions observable combining it with standard therapy, a recommendation for the use ofd,l-methadone in glioblastoma therapy cannot be given. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
ConclusionsXELOX-trastuzumab is a promising and effective therapy as first-line treatment for patients with HER2-positive AGC, with comparable results to the ones obtained with other “platinum-based” regimens. This scheme is feasible and tolerable with a low incidence of cardiac toxicity. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5 ′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil
ConclusionRabeprazole does not affect capecitabine pharmacokinetics. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability
AbstractBecause of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might b...
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias
ConclusionsFLAG regimen was found superior to FLAG-IDA with better survival and subsequent transplant rate. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model
AbstractIrinotecan-induced mucositis is a major oncological problem. Goblet cells secrete mucus, protecting the intestinal mucosa, with secretion altered during mucositis. The enteric nervous system is involved in regulating gut motility and secretion. The aim of this study was to determine whether enteric neural cells and goblet cells are altered following irinotecan treatment. Tumour-bearing Dark Agouti rats were administered a single dose of 175  mg/kg of irinotecan intraperitoneally and 0.01 mg/kg atropine subcutaneously. Experimental and untreated control rats were killed at times 6, 24, 48, 72, 96 and 120&n...
Source: Cancer Chemotherapy and Pharmacology - April 10, 2019 Category: Cancer & Oncology Source Type: research

Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
ConclusionsThe PK and safety profile of olaparib monotherapy in Chinese patients is consistent with that seen previously in Western and Japanese patients, and the recommended Phase III monotherapy tablet dose (300  mg bid) is suitable for use in this population. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - April 10, 2019 Category: Cancer & Oncology Source Type: research

The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis
This study aimed to explore the role and mechanism of long noncoding RNA plasmacytoma variant translocation 1 (PVT1) in cisplatin sensitivity of NSCLC.MethodsPaired tumor and adjacent tissues were collected from forty patients with NSCLC. The clinical value of PVT1 was investigated according to clinicopathological parameters of patients. Cisplatin-sensitive or -resistant cells (A549 or A549/DDP) were used forin vitro experiments. Cell viability, apoptosis, autophagy and animal experiments were conducted to investigate cisplatin sensitivity. The expressions of PVT1, microRNA-216b (miR-216b) and apoptosis- or autophagy-relat...
Source: Cancer Chemotherapy and Pharmacology - April 10, 2019 Category: Cancer & Oncology Source Type: research